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Detailed characterization of cell type transitions is essential for cell biology in general and
particularly for the development of stem cell-based therapies in regenerative medicine. To
systematically study such transitions, we introduce a method that simultaneously measures
protein expression and thermal stability changes in cells and provide the web-based visua-
lization tool ProteoTracker. We apply our method to study differences between human
pluripotent stem cells and several cell types including their parental cell line and differentiated
progeny. We detect alterations of protein properties in numerous cellular pathways and
components including ribosome biogenesis and demonstrate that modulation of ribosome
maturation through SBDS protein can be helpful for manipulating cell stemness in vitro. Using
our integrative proteomics approach and the web-based tool, we uncover a molecular basis
for the uncoupling of robust transcription from parsimonious translation in stem cells and
propose a method for maintaining pluripotency in vitro.
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Understanding transitions from one cell type or state toanother is in the focus of modern molecular biology. Cell-type transitions play a central role in disease modelling,
tissue engineering, and regenerative medicine1–4. These transi-
tions are enacted by profound changes in protein composition of
the cells. In general, proteins regulate their activity by changes in
either expression or structure, the latter is often triggered by post-
translational modifications (PTMs)5. Structural changes fre-
quently lead to alterations in protein solubility, which is emerging
as one of the most important parameters modulating protein
function6. To get a new insight into pluripotency, we employed a
plurifaceted experimental design combining expression pro-
teomics with the proteome-wide integral solubility alteration
(PISA) assay7 to compare pluripotent cells with their isogenic
progenies and parental cells as well as with allogeneic cells. PISA
is a high throughput version of thermal proteome profiling (TPP)
or CETSA-MS8,9. Thermal profiling performs proteome-wide
assessment of protein solubility interpreted as their thermal sta-
bility, via the melting curves acquired across a temperature range
using multiplexed proteomics10. This method adds another
dimension to the standard proteomics approaches, which are
largely based on quantification of protein abundances and/or the
occupancies of their PTMs. TPP is able to detect small changes in
solubility or thermal stability of proteins occurring due to the
binding of small molecules to proteins in living cells and cellular
lysates, post-translational modifications11, and large macro-
molecular complex dynamics12, for example during transitions
through the eukaryotic cell cycle13,14. Recently, TPP has been
used to measure and compare the protein melting temperatures
across thirteen different species; the study demonstrated that
genomic alterations can affect protein thermal stability15.
Importantly, changes in protein solubility/stability are found to be
complementary to changes in protein abundances7. The com-
bined proteomic approach called PISA-Express implemented here
uses just two samples per replicate analysis of a cell type (Fig. 1a,
b) to assess both the protein abundance and solubility. In con-
trast, TPP alone usually requires analysis of 10 samples16. Fol-
lowing the established tradition, we will interpret the measured
solubility alterations as thermal stability changes, bearing in mind
that the relation between solubility and stability is actually more
complex17.
In this study, we present a method for simultaneously mea-
suring protein expression and thermal stability after cell-type
transition as well as a multidimensional visualization tool, Pro-
teoTracker, based on Sankey diagrams, to study proteome
changes without dimension reduction. (Supplementary Fig. 1a, b)
(available at http://www.proteotracker.genexplain.com). By ana-
lyzing the Sankey diagrams, we detect alterations in protein
properties after transition between PSCs and other cell types and
map the altered proteins to various pathways and compartments,
such as chromatin remodeling, DNA replication, cytoskeleton,
cell adhesion, glucose metabolism, and ribosomes. This combined
analysis provides a more detailed view of protein behavior that is
difficult to obtain from transcriptomic, expression proteomic or
TPP analysis only. Lastly, we show that SBDS protein, which is
involved in ribosome biogenesis, plays a role in stem cell main-
tenance and differentiation, and could be targeted to modulate
pluripotency in vitro.
Results
Protein thermal stability and expression changes during cell-
type transitions. In order to acquire cell lineages that are relevant
for regenerative medicine, we reprogrammed hFFs into iPSCs
(Supplementary Figs. 2 and 3) and differentiated the latter into EBs
using an undirected method (Methods). EBs have been used as a
model of early developmental specification and as a starting point in
numerous protocols for differentiation of specific cell types, thus
representing a valuable tool to study general differentiation processes
in pluripotent stem cells18–27. We also included to the study a well-
known human ESC line H9 as a standard of pluripotency that is
allogeneic to the hFFs and iPSCs. Colon cancer cell line RKO was
added to the analysis to provide a qualitative and quantitative point
of comparison for changes in protein properties occurring between
cells from the same parental lineage and sex (iPSCs, hFF and EBs),
and cells harboring chromosome rearrangements, various point
mutations, and a different sex (RKO)28. In addition, RKO cells divide
fast29 and at a similar rate or faster than iPSCs, allowing one to
correct at least partially for potential cell division rate bias (Supple-
mentary Fig. 4a). For simplicity, we used the terms “differentiated
cells” to designate all the nonpluripotent cell types used in this study.
The use of five cell lineages allowed us to fit the full replicate of the
PISA-Express analysis within a single proteomics experiment by
multiplexing ten tandem mass tags (TMT10). One tenths of every
sample, including the replicates, was pooled and labeled by TMT11,
and then added to each TMT10 multiplexed sample as a linker, i.e.,
internal standard (Fig. 1c). Subsequently, the obtained samples were
fractionated and analyzed by LC-MS/MS. Thus, in one multiplexed
analysis we obtained information on three dimensions, or facets,
namely, thermal stability, expression, and degree of differentiation
(transiting from pluripotent cells via partially differentiated EBs to
fully differentiated hFFs).
In three replicate analyses, we obtained stability and expression
data for 9509 proteins, including scarcely expressed master
pluripotency markers OCT4 and NANOG. In total, 7778 proteins
passed our selection criteria of being identified by at least two
unique peptides with no missing values in any replicate and cell
type (Supplementary Data 1). For each protein, we calculated the
PISA parameter Sm for protein stability where larger Sm value
indicates higher thermal stability and vice versa. We also
calculated the Exp value for protein expression as the average
between three biological replicates (Fig. 1d). For consistency, in
both cases the input parameter was the ratio of the TMT reporter
ion abundance to that of the linker.
To validate our findings, we increased the proteome depth and
sequence coverage in protein expression analysis during differ-
entiation of iPSC and ESC into EBs by using strong detergent
(sodium dodecyl sulfate) and quantified 11,451 proteins with
9565 proteins passing our selection criteria (Supplementary
Data 2). Additionally, we acquired protein expression datasets
on HT29 cells and neurons differentiated from iPSCs hi12, as well
as hFF, hi12, and EBs for comparison. The datasets encompass
9000 proteins, of which 5478 passed our selection criteria
(Supplementary Data 2), as described in Methods.
Protein thermal stability distinguishes cell types independently
from protein expression. To investigate how well the Sm and
Exp parameters distinguish cell types, we performed principal
component analysis (PCA) for all five cell lineages. The PCA plots
showed little separation between the iPSCs and ESCs, both for
protein stability and expression (Fig. 2a, b). In general, the 1st
component in both PCA dimensions aligned with the degree of
differentiation of the cells, positioning hFF on the one side and
the two PSCs on the other side on each plot. The EBs, which arose
from random differentiation and contained some proportion of
pluripotent and progenitor cells30, were found in an intermediate
position. RKO cells were most distant from PSCs on the stability
plot but in an intermediate position on the expression plot.
Proteins of iPSCs did not correlate with those of hFF, RKO, or
EBs in either stability or expression, while the Pearson correlation
coefficients with ESC proteins were 0.85 and 0.86, respectively
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(Supplementary Fig. 4c, d). For each protein, fold changes (FCs)
of Sm and Exp were calculated compared to those of the iPSC
population, as well as the standard deviations of these values
across the whole dataset. The mean standard deviations of Sm
and Exp were also calculated for all proteins. The number of
statistical outliers exhibiting more than three mean standard
deviations was similar for both expression and stability (Fig. 2c).
Since point mutations can alter protein thermal stability15,31–33
and expression34–36, we expected to see the largest differences in
RKO compared to other cell types. However, to our surprise, hFF
(male) had similar numbers of outliers in stability and higher
number of outliers in protein expression than RKO (female)
when both were compared to iPSCs (male). On the other hand,
ESCs (female) had the lowest numbers of outliers and showed
almost no changes compared to iPSCs (male). These observations
suggest that such characteristics as cell identity and/or culture
conditions contribute more to the differences in protein proper-
ties than the genetic makeup of the cells.
Lastly, we did not observe a significant correlation between the
FCs in stability versus expression for individual proteins7,13,14,
confirming that changes in these two analytical dimensions are
independent when comparing different types of cells (Supplemen-
tary Fig. 4b). Although the maximum FC amplitude was higher in
expression than in stability (Fig. 2c), in PCA the separation between
different cell types were similar in the two analysis facets.
ProteoTracker maps protein trajectories in cell-type transi-
tions. Protein trajectory between two cell types is determined as a
vector in the two-dimensional space of protein stability and
expression, with one cell type providing the origin (Fig. 2d). Each
protein trajectory falls into one of the five sectors denoted from A
to E (Fig. 2e). Sector A included trajectories of proteins that are
thermally stabilized and upregulated in the final cell type in
comparison with the origin. Similarly, sectors B, C, and D
encompass trajectories of stabilized and downregulated, destabi-
lized and downregulated and destabilized and upregulated pro-
teins, respectively. All protein trajectories in sectors A–D have a
combined (via Fisher formula37) p-value < 0.05 while all other
trajectories were considered statistically insignificant and assigned
to sector E that includes the origin (Fig. 2e). In a unidirectional
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Fig. 1 Protein thermal stability and expression changes in cell-type transitions. a Cells of different types in were grown simultaneously (n= 3 biologically
independent samples per cell type). b Cells were collected and heated in a narrow temperature range, with one sample incubated at 37 °C for expression
measurements, protein aggregates were eliminated by ultracentrifugation and the soluble proteins were digested. c 1/10 portions of each sample were
integrated into a pooled sample and digests were labelled by TMT11 and multiplexed. d The same pooled sample was used in all multiplexed sets for
normalization or reporter ion abundances PISA parameter (Sm) and expression fold change (Exp) were calculated, and protein trajectories during cell
transitions were charted using a Sankey diagram.
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evolution of protein trajectories using a Sankey diagram, in which
each of the sectors A–E assigned to a protein trajectory in the first
transition transforms to the sector A–E assigned to the trajectory
of the same protein in the second transition (Fig. 2e). As an
example, in the transition iPSC→EB→hFF, a protein that is
stabilized and downregulated (sector B) in iPSC→EB as well as
destabilized and upregulated (sector D) in EB→hFF will be
classified as a B to D type.
Using this methodology, we studied the proteome conversion
from iPSC to hFF via EB as an evolution of two trajectories (Tn),
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EB versus iPSC (T1), and hFF versus EB (T2), with the general
direction from pluripotency to terminal differentiation, bearing in
mind that EBs are not a fixed cell type but are comprised of a
heterogeneous population of pluripotent and progenitor stem
cells as well as cells with various degrees of differentiation within
many lineages. Gene Ontology (GO) enrichment analysis was
performed on each protein trajectory transition group (PTTG)
that encompassed proteins undergoing transition from one
defined sector to another, for instance from A to A, B to A, etc.
(Fig. 2d, e). For each protein and transition, the trajectory length
was calculated as a distance to the origin, and their distributions
for the corresponding PTTG were plotted to compare the
magnitudes of changes in protein properties. The mean distances
are shown as vertical lines in the distribution plots (Fig. 2e, right),
while the number of proteins and the percentage of proteins in
the final sector of each PTTG are also given.
The diagram shows that more than 75% of the proteome
significantly changed either expression or stability during the two
transitions. The most populated significant (i.e., excluding the
sector E) PTTG was B to B, which according to GO enrichment
analysis encompasses DNA replication initiation, nucleoplasm
and DNA binding. PTTG B to A shows the highest mean distance
of trajectories in both T1 and T2 and the highest fold enrichment
in GO analysis, with all three most enriched GO terms related to
ribosome.
ProteoTracker reveals progression of molecular pathways
during PSC differentiation. Next, we investigated the progres-
sion of key pathways that were enriched in the GO analysis of
protein transitions during differentiation of PSCs into EBs. The
mean protein distance on T1 in each pathway was normalized
such that the distance from the pluripotency state (iPSC) to the
terminal differentiation state (hFF) was equal to one unit. Thus,
normalized mean magnitude of each pathway for the progression
from iPSC to EB was then depicted (Fig. 3a). For cellular amino
acid metabolic process, this magnitude of progression was larger
than unity, suggesting a forth-and-back modulation of this
pathway during differentiation. The pathways related to glyco-
lysis, oxidative phosphorylation, mitochondrial inner membrane,
and ribosomal components showed progression close to unity,
suggesting the important role of these pathways in early differ-
entiation. The DNA repair, chromatin remodeling, and DNA
replication pathways showed much lower progression, hinting
that metabolic reprograming precedes the DNA- and chromatin-
related changes during differentiation.
To interrogate the data at a different angle, we calculated the
position of EBs on a two-dimensional plot composed of the 1st
PCA components of stability and expression for each pathway,
normalized such that the coordinates of iPSCs are (0, 0) and those
of hFF are (1, 1) (Fig. 3b). Strikingly, on this plot the structural
component of ribosome was off-scale for expression, albeit close
to 0.5 in stability. This hinted that ribosomal proteins’ expression
might play a triggering role in PSC differentiation (see below).
Mitochondrial inner membrane, glycolysis, oxidative phosphor-
ylation, and cellular amino acid metabolic processes showed
similar progression magnitudes for both expression and stability.
These magnitudes were higher than for DNA repair, DNA
replication, and chromatin remodeling, which shared comparable
progression values, similar to their proximity on Fig. 3a.
While metabolic switch and activation of mitochondria are
required for cell differentiation38,39, so is the closure of the open
chromatin state in PSCs40. However, the timing of these two
molecular events has not been fully elucidated. Here, hFF and
RKO cells exhibited higher rate of oxidative metabolism and
higher respiratory capacity than PSCs (Supplementary Fig. 5c–e).
Additionally, EBs had similar expression and stability profiles of
proteins involved in glycolysis and oxidative phosphorylation to
those of hFF and RKO cells, suggesting that the cells EBs are
composed of, at this differentiation stage, mostly rely on oxidative
phosphorylation while PSCs uses glycolysis (Supplementary
Fig. 5a, b). PSCs are known to have a lower proportion of
heterochromatin than differentiated cells rendering the chroma-
tin of pluripotent cells chromatin to be more loose40–43. The open
state of chromatin in PSCs is maintained by a specific expression
pattern of chromatin-remodeling complexes40. Here we detected
gradual increase in histone stability and changes in expression
and stability of chromatin-remodeling complexes during differ-
entiation of PSCs, showing that chromatin in EBs is on average
not yet at a fully compacted state characteristic of terminally
differentiated cells (Supplementary Fig. 5f–k). Thus, our analysis
suggests that metabolic reprograming from glycolysis to oxidative
phosphorylation might happen earlier than chromatin rearrange-
ments during early differentiation. This is in line with previous
predictions44.
Ribosomal proteins increase in stability during differentiation
of PSCs. Since ‘the ribosome’ was one of the most enriched GO
terms in the transition analysis (Fig. 2e) and an outlier in the
progression analysis (Fig. 3b), we investigated ribosomal proteins
in detail. These proteins were significantly stabilized in differ-
entiated cells compared to PSCs (Fig. 3c–g). Expression of ribo-
somal proteins was somewhat similar in PSCs, hFFs and RKO,
but significantly lower in EBs (Fig. 3c–g). We also performed TPP
of hFFs in comparison with two iPSC lines, hi11 and hi13, and
confirmed the increased thermal stability of ribosomal proteins in
differentiated cells (Supplementary Fig. 6a, b and Supplementary
Data 3). Notably, there was no apparent correlation between the
ribosomal protein expression and their thermal stability.
Ribosomal proteins stabilization during differentiation stems
from changes in ribosomal structure. We hypothesized that the
ribosomal proteins’ stabilization during differentiation of PSCs
originates from a difference in the structure of ribosomes rather
Fig. 2 Charting protein trajectories during cell-type transitions using combined protein stability and expression analysis. a PCA plot of protein stability
(Sm) in hi12 iPSC, H9 ESC, EB, hFF, and RKO cells. b PCA plot of protein expression (Exp) in each cell type. c Violin plots showing the distribution of Sm and
Exp FC of each cell line against iPSC and number of proteins with a log2 fold change (FC) in stability and expression exceeding three standard deviations in
each cell line compared to iPSC. Horizonal line in the boxplots represent the median, 25th and 75th percentiles and whiskers represent measurements to
the 5th and 95th percentiles. d Protein trajectories during cell-type transitions were defined as positions in a 2D plot of log2 of FCs for Sm and Exp
compared to the original type. Transition (T1) was from pluripotency (iPSC) to early differentiation (EB), and (T2) from EB to terminal differentiation (hFF).
e Sankey diagram based on assigning to a significant sector (A–D) a protein trajectory in (T1) and (T2) when the combined p-value for changes in stability
and expression was <0.05, and to an insignificant sector E otherwise. Each protein trajectory transition group (PTTG) of proteins undergoing transition
from a sector X in (T1) to a sector Y in (T2) (25 PTTGs in total) was submitted to a Gene Ontology (GO) enrichment analysis with all quantified proteins as
background. For each sector in PTTG, the density distribution of the distances on the 2D plot in (T1) and (T2) is plotted and the percentage of proteins
transiting from any sector in T1 to sector Y is calculated, and their number is given. Source data are provided as a Source Data file.
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than from the changes in intracellular environment. To test this
hypothesis, we performed TPP in cell lysates, in which intracel-
lular environment affects protein melting behavior to much lesser
degree than in intact cells12. Ribosomal proteins had higher
average melting temperatures (Tm) in the hFF lysates than in
iPSC lysates, confirming the results in living cells (Supplementary
Fig. 6c and Supplementary Data 3) and supporting our
hypothesis.
iPSCs have lower proportion of functional ribosomes than
RKO. To investigate the difference in ribosomal structure in
different cell types, we fractionated cell lysates from iPSCs and
RKO cells using a 10–50% linear sucrose gradient while recording
the absorption at 245 nm. iPSCs demonstrated more abundant
60S subunits (immature ribosomes) with fewer 80S subunits
(mature ribosomes) and polysomes compared to RKO cells
(Fig. 4a, b). The fractions corresponding to the free proteins, 40S
and 60S ribosomal subunits, mature 80S ribosomes, light poly-
somes and heavy polysomes were analyzed by proteomics, which
did not reveal significant differences at either protein or peptide
levels (Supplementary Fig. 6f–j and Supplementary Data 2). Thus,
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Fig. 3 ProteoTracker determines timing for molecular events and shows that ribosome is the most affected protein complex during differentiation of
PSCs. a Differentiation scale determined by the mean distances on T1 and T3 normalized by T3 for selected pathways in iPSC, EB, and hFF. b Differentiation
scale determined by distances to iPSC on PCA of the mean Sm and Exp of proteins in each selected pathway in iPSC, hFF, and EB normalized by the
distance between hFF and iPSC. c ProteoTracker analysis of ribosomal proteins trajectories in transitions (T1) and (T2). d–g Two-dimensional plots of mean
Sm and Exp FCs in H9 ESC, EB, hFF, and RKO against hi12 iPSC. Source data are provided as a Source Data file.
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from a difference in ribosomal proteins’ stoichiometry. There are
also doubts that it was caused by a difference in PTMs, as the
latter would reduce the level of unmodified peptides, which may
result in altered expression read-outs. Translating ribosomes and
particularly polysomes appear to be more thermally stable than
immature 40S, 60S subunits, or free ribosomal proteins12. Thus,
higher average thermal stability of the ribosomal pool in somatic
cells is likely due to a higher proportion of fully assembled
ribosomal complexes and polysomes.
iPSCs exhibit lower levels of translation than somatic cells.
RKO and iPSCs cells showed similar expression levels of ribo-
somal proteins, while RKO cells had a higher proportion of
functional ribosomes (80S and polysomes). Taken together these
results suggest that iPSCs have a lower protein synthesis rate than
differentiated cells, in line with previous reports45. Reduced
protein synthesis capacity due to a lower proportion of functional
ribosomes has been shown for Saccharomyces cerevisiae46. To
assess the global protein synthesis rates in iPSCs, RKO, and hFF
cells, we used incorporation of a puromycin analogue into newly
translated proteins (Click-iT® Plus OPP Protein Synthesis Assay).
As expected, the pluripotent cells exhibited significantly reduced
mean protein synthesis rate in comparison with that of hFF and
RKO cells (Fig. 4c, d and Supplementary Fig. 6k).
SBDS is downregulated in iPSCs in comparison with somatic
cells. To understand the molecular basis for the decrease in sta-
bility of ribosomal proteins in pluripotent cells and its link to the
reduced protein synthesis rate, we investigated the expression of
proteins involved in ribosome biogenesis in several cell lineages,
including iPSCs, neuronal cells (Supplementary Fig. 7a, b) and
EBs differentiated from the iPSCs, parental hFFs, HT29, and RKO
cells. We determined the expression levels for 5478 proteins that
passed our criteria across all cell types. SBDS protein showed the
lowest mean expression in iPSCs compared to differentiated cell
types, being the only ribosome biogenesis-related protein down-
regulated in iPSCs compared to any tested differentiated cell line,
and anticorrelating in expression levels with other ribosome
biogenesis factors (Fig. 5a–c Supplementary Data 2). SBDS pro-
tein expression profiles in hFF and iPSC were corroborated by
microarray analysis of mRNA showing that SBDS mRNA is
present in lower quantities in iPSCs than in hFF (Supplementary
Data 4). SBDS presence is necessary in the late steps of 60S
ribosomal subunit maturation, critical for the assembly of
translation-competent ribosomes47,48. SBDS cooperates with
EFL1 for ejecting EIF6 from immature 60S subunit that leads to
association of a 60S subunit and a 40S subunit into a functional
80S ribosome49. Therefore, the deficit of SBDS in iPSCs may
hamper the assembly of mature ribosomes and formation of
polysomes resulting in the observed lower protein synthesis rate.
SBDS knockdown (KD) reduces protein translation in hFFs. To
test if downregulation of SBDS reduces the protein synthesis rate,
we treated hFFs with siRNA against SBDS and scrambled siRNA
(control). SBDS knockdown (KD) was confirmed with LC-MS/
MS (Supplementary Data 2), revealing a downregulation of SBDS
to 50 and 45% after 2 and 4 days of treatment, respectively
(Supplementary Fig. 6d, e). Although the remaining SBDS levels
were still higher than in iPSCs, SBDS KD hFFs showed significant
reduction in the global protein synthesis rate in comparison with
hFFs treated with the control siRNA (Fig. 5d).
SBDS exhibits opposite expression pattern compared to plur-
ipotency markers and other ribosome biogenesis factors during
differentiation of PSCs. To study SBDS expression during PSC
differentiation, we performed LC-MS/MS analysis of iPSCs and
EBs formed from the iPSCs at different time points of the dif-
ferentiation process (Fig. 6a and Supplementary Data 2). SBDS
expression steadily increased starting from day 6 of the iPSCs
differentiation. Importantly, SBDS expression had significant
opposite expression trend compared to that of the master plur-
ipotency markers OCT4 and NANOG (Fig. 6b), as well as to the
mean expression of other ribosome biogenesis factors and ribo-
somal proteins over the 9 days long course of the EB induction
(Fig. 6c). Real-time quantitative PCR (qRT-PCR) analysis con-
firmed the increase in SBDS transcription and the decrease in
OCT4 and NANOG transcription at day 9 of the iPSCs differ-
entiation (Fig. 6d).
Recently, Kanton et al. have analyzed PSC differentiation into
cerebral organoids using single-cell transcriptomics and provided
a tool for reconstruction of differentiation trajectories from
pluripotency through neuroectoderm and neuroepithelial stages
followed by divergence into various neuronal fates50. Using the
tool for the analysis of human ESC line H9 and human iPSCs line
409b2 differentiation, we visualized expression of OCT4,
NANOG, and SBDS along the differentiation trajectories and
confirmed the downregulation of SBDS expression in OCT4- and
NANOG-positive cells in comparison with that in differentiating
and differentiated neuronal cells (Supplementary Fig. 7c–e).
To further validate SBDS deficit in PSCs, we formed EBs from
human ESC lines H9 and HS980, and compared protein
expression profiles in the human ESCs, EBs at the 9th day of








































































Fig. 4 iPSCs have lower polysome content and protein synthesis rate
than differentiated cells. a Ribosome density profile on a 10–50% sucrose
gradient of hi12 iPSC lysates against that of RKO cells. b Analysis of the
area under the curve (A.U.C.) of several fractions of the ribosome profile
(n= 2 biologically independent samples). c Measurement of OPPuro
incorporation in hi12 iPSC, hFF, and RKO. The gating strategy is described in
Supplementary Fig. 6k. d Analysis of mean fluorescence intensity (MFI)
from OPPuro incorporation in hi12 cells, hFFs and RKO cells (n= 3
biologically independent samples for each cell line). P-values were
calculated using a two-sided Student t-test. p < 0.05 were considered as
significant. Error bars represent ±the standard deviation of the mean.
Source data are provided as a Source Data file.
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Data 2). SBDS levels were significantly higher in EBs and hFFs
compared to those in ESCs; the differences were on par with those
observed in the experiments with differentiation of iPSCs
(Supplementary Fig. 8a, c, d, e and Supplementary Data 2).
Moreover, SBDS expression in human ESCs and their EBs also
showed opposite expression patterns compared to those of the
ribosomal proteins and ribosome biogenesis factors as well as
OCT4 and NANOG.
SBDS KD maintains pluripotency and SBDS knockin decreases
the expression of pluripotency markers in PSCs. Finally, EBs
were also treated with siRNA against SBDS and control scram-
bled siRNA at day 6 of the EB induction and analyzed at day 9
(Fig. 6a). The qRT-PCR analysis showed significant down-
regulation of SBDS mRNA levels and significant upregulation of
OCT4 and NANOGmRNAs in SBDS KD EBs in comparison with
controls (Fig. 6e). SBDS siRNA treatment decreased SBDS
expression to 61% as well as globally reduced expression of
proteins that, according to GO annotation, are involved in ana-
tomical structure and organ development processes. This result
confirmed the decreased ability of iPSCs to differentiate upon
SBDS downregulation (Fig. 6f, Supplementary Data 2). To assess
the reproducibility of the significance cutoff that we used, a
permutation analysis of the replicates was performed. In 57,390
unique permutations, only two proteins showed significantly
altered expression (false positives) using our cutoff, while 155 out
of 9565 proteins had significantly altered expression in the ana-
lysis of treated samples versus controls.
The above observations were confirmed by transferring iPSCs
onto Geltrex™, which is known to induce more spontaneous
differentiation than laminin-52151, and treating the cultures with
two different siRNAs against SBDS and two scrambled siRNA
controls. The SBDS mRNA level was reduced by around 50% in










































































































































































































Fig. 5 SBDS controls protein synthesis rate in iPSCs. a Expression of proteins involved in ribosome biogenesis in hi12 iPSCs compared to that in parental
hFFs, EBs, and neuronal cells differentiated from hi12 iPSCs, HT29, and RKO cells (n= 3 biologically independent samples). b Ranking of all ribosome
biogenesis factors according to the reversed mean correlation of their expression against each other individual ribosome biogenesis factors’ expression in
all the cell lines mentioned above. c Expression of the ten most downregulated ribosome biogenesis factors in each cell line compared to that in hi12 iPSC.
Boxplots of SBDS, EIF6, and EFL1 proteins are colored in purple, orange, and blue, respectively, while other proteins are colored in gray (n= 3 biologically
independent samples). Horizonal line in the boxplots represent the median, 25th and 75th percentiles and whiskers represent measurements to the 5th and
95th percentiles. d OPPuro incorporation measurement in SBDS siRNA and scrambled siRNA (control) treated hFFs 3 days after the treatment, data were
normalized to the mean fluorescence intensity in the scrambled siRNA control (n= 6 biologically independent samples). Error bars represent ±the standard
deviation of the mean. P-values were calculated using a two-sided Student t-test. p < 0.05 were considered as significant. Source data are provided as a
Source Data file.
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Fig. 6 SBDS protein is involved in differentiation and pluripotency maintenance in PSCs. a Schematic representation of PSCs differentiation into EBs and
subsequent SBDS siRNA and scrambled siRNA treatments. b Protein expression of SBDS, OCT4, and NANOG in EBs at different days of their induction
normalized to that in hi12 iPSCs at day 0. c Expression of SBDS protein, mean ribosomal proteins expression (Rps) and mean expression of proteins
involved in ribosome biogenesis (RBps) encompassing 81 and 237 unique proteins, respectively, in EBs normalized to that in hi12 cells at day 0. Error bars
represent ±the standard deviation of the mean. d Relative abundance of SBDS, OCT4, and NANOG mRNAs after nine days (D9) of EBs induction versus
that in day 0 (D0) hi12 cells measured using qRT-PCR. e Relative abundance of SBDS, OCT4, and NANOG mRNAs in day 9 EBs after three days of SBDS
siRNA and scrambled siRNA treatments. f Relative protein abundance in day 9 EBs after 3 days of SBDS siRNA treatment versus that in the day 9 EBs
treated with scrambled siRNA (control); and top three most significantly up or downregulated pathways according to GO annotation (P < 0.05 and relative
expression <0.8 or >1.25) (n= 3 biologically independent samples). P-values were calculated using Welsh’s t-test for proteomics experiment and using a
two-sided Student t-test for qRT-PCR. p < 0.05 were considered as significant. Horizonal line in the boxplots represent the median, 25th and 75th
percentiles and whiskers represent measurements to the 5th and 95th percentiles. n= 3 biologically independent samples for proteomics experiments and
n= 4 biologically independent samples for qRT-PCR data. Source data are provided as a Source Data file.
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knockdown significantly increased the mRNA level of the master
pluripotency marker OCT4 and, overall, significantly decreased
mRNA levels of lineage specific markers including SOX7
(endoderm), SOX17 (endoderm), GATA4 (mesoderm), and
PAX6 (ectoderm) in comparison with the control iPSCs (Fig. 7a,
b). Furthermore, SBDS KD in ESCs H9 led to a significant
increase in mRNA levels of both OCT4 and NANOG and a
significant decrease in mRNA levels of lineage markers SOX7 and
GATA4 (Fig. 7c). Importantly, both SBDS siRNAs treatment did
not significantly alter pluripotent stem cells viability and
proliferation (Supplementary Fig. 8b). Lastly, knockin of SBDS
protein decreased mRNA levels of OCT4 in iPSC hi12 (Fig. 7d)
and of OCT4 and NANOG in ESCs H9 (Fig. 7e).
Discussion
Here, we provide the proteome signature resource ProteoTracker
comprising a plurifaceted dataset and online software for com-
prehensive system-wide analysis of thermal stability and expres-
sion level changes of proteins and apply this tool for comparing
several isogenic and allogeneic cell types including well-defined
pluripotent cells. We observed that protein thermal stability
distinguished cell types and degrees of differentiation on the same
scale as protein expression. The visualization feature of Proteo-
Tracker helped interrogating our plurifaceted dataset, mapping
changes in protein properties after cell-type transitions on an
easily interpretable Sankey diagram. Rather uniquely, Sankey
diagrams visualize multidimensional system-wide proteome
transitions in form of 2D maps without reduction of the under-
lying dimensionality. Importantly, our dataset and interface can
be both expanded to include more types of somatic and plur-
ipotent stem cells and be used for analysis of other transitions
within and between cell lineages, particularly the transitions
between somatic stem cells and their differentiated progeny.
Using the ProteoTracker tool, we studied protein trajectories
between isogenic cell types and detected alterations of protein
properties in multiple cell compartments and pathways, reflecting
fundamental differences in cell physiology and morphology
between somatic cells and PSCs. Some of the changes could arise
from differences in the growth conditions. Our analysis shows
that more than 75% of the proteins present in our dataset vary
significantly in expression and/or stability between the plur-
ipotent and differentiated cell types. Particularly, expression and/
or stability of histones and chromatin remodelers, including SWI/
SNF and Mi2/NuRD families, were altered between PSCs and
differentiated cells. This can be attributed to the particular
chromatin landscape in PSCs and suggests that our approach is
suitable to study chromatin compaction. We also found that EBs
already exhibit expression and stability patterns of metabolic
enzymes similar to those of differentiated cells before achieving
the levels of chromatin compaction characteristic of terminally
differentiated cells. Finally, our analysis of timing of activation of
the molecular pathways suggests that the metabolic switch is
occurring in the early stages of PSCs differentiation, and as it
happens before the complete rearrangement of the chromatin, it
may be the trigger of the latter process44.
The most intriguing finding relates to the role of ribosomes in
stemness maintenance and cell differentiation. We discovered
thermal destabilization of ribosomes in PSCs and gradual increase
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Fig. 7 SBDS knockdown promotes maintenance of pluripotency and knockin decreases expression of pluripotency markers in PSCs. Relative mRNAs
abundance of pluripotency (OCT4 and NANOG) and lineage specific markers (SOX7, SOX17, GATA4, and PAX6) after 3 days of scrambled siRNA 1 and
SBDS siRNA 1 treatments (a) or scrambled siRNA and SBDS siRNA 2 treatments (b) in iPSCs hi12 and scrambled siRNA 2 and SBDS siRNA 2 treatments in
ESCs H9 (c) grown on Geltrex™. Relative mRNAs abundance of pluripotency markers (OCT4 and NANOG) after knockin of SBDS protein in hi12 (d) and
H9 (e). Horizonal line in the boxplots represent the median, 25th and 75th percentiles and whiskers represent measurements to the 5th and 95th
percentiles. ND nondetected. P-values were calculated using a two-sided Student t-test. p < 0.05 were considered as significant. n= 4 biologically
independent samples for all experiments. Source data are provided as a Source Data file.
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confirmed earlier suggestions that increased thermal stability of
ribosomal proteins is linked to a higher proportion of mature
ribosomal complexes12. Using ribosome density profiling, we
showed that PSCs possess lower levels of mature ribosomes than
differentiated cells. The decreased ribosome stability in plur-
ipotent cells explains the decreased protein synthesis rate despite
high division rate and, in general, higher expression levels of
ribosomal proteins and ribosome biogenesis factors than in dif-
ferentiated cells. Taken together, the provided evidence explains
the reported inefficacy of translation in pluripotent cells45,52.
Using our approach, we also identified SBDS protein as the
ribosomal factor that helps maintaining pluripotency in PSCs. It
has been shown that SBDS is a key component in the late stage of
ribosome maturation and its deficit inhibits association of ribo-
some subunits into mature 80S ribosomes, thus limiting the
translation rate47. Here, we showed that differentiation of PSCs is
associated with an increase in SBDS abundance and is impaired
by SBDS knockdown. The former corroborates the reported
increase of translation efficiency during differentiation of
PSCs45,52, while the latter suggests a role of SBDS in inhibiting
spontaneous differentiation during the self-renewal of PSCs.
Conversely, SBDS knockin was characterized by a decrease in
expression of the pluripotency markers. Our data suggest that
physiologically low level of SBDS in PSCs helps maintaining
pluripotency via control of the protein translation rate by sup-
pression of the ribosome maturation and that on the contrary,
higher expression levels of SBDS may promote the exit from
pluripotency. This finding also provides an explanation to the
putative discrepancy between the elevated transcriptional41 and
lowered translational45 activities that are known features of PSCs.
These results are consistent with the earlier findings that muta-
tion in the SBDS gene or SBDS knockdown do not affect long-
term self-renewal of PSCs53.
Mutations in the SBDS gene that reduce expression of func-
tional SBDS protein are known to induce an immature ribosome
phenotype similar to the one demonstrated here in PSCs and to
cause Shwachman-Diamond-Syndrome (SDS)54. SDS is a genetic
ribosomopathy that causes bone marrow disorders as well as
various organ malformations, including skeletal and neuronal
disorders in the patients55,56. The bone marrow phenotype in
SDS affects the ability of hematopoietic stem cells to differentiate
rather than reduces the stem cell pool itself45. This is analogous to
the effect of SBDS knockdown in differentiating cells demon-
strated here. Our data further suggest that apart from causing the
bone marrow phenotype, the altered SBDS expression also
impairs the ability of pluripotent cells to differentiate, thus pro-
viding a new insight into other developmental defects observed in
patients with SDS.
Several types of somatic stem cells have been shown to restrict
their translation rate and to increase it upon differentiation57–59,
suggesting that lowering translation rate is important for main-
taining cell stemness. In addition, Kruta et al.60. have recently
shown that inhibition of protein synthesis facilitates maintenance
of HSCs in vitro. We speculate that inhibition of SBDS might be a
useful universal approach for maintaining stem cells in vitro.
In conclusion, our data on the proteins involved in chromatin
remodeling, DNA replication machinery, metabolism, and ribo-
some stability confirm that this plurifaceted proteomics dataset
and the interpretation tool can be used to study stem cell related
and other cell-specific phenomena. Here, we only explored a few
features of the proteome conversion, leaving a multitude of
intriguing findings for further functional exploration and dis-
coveries. This plurifaceted proteomic approach may prove to be a
useful tool in finding optimal conditions for proliferation of
various cells, including self-renewal of stem cells, designing dif-
ferentiation and trans-differentiation protocols and mechanistic
studies on particular proteins functions. We expect that PISA-
Express proteomics coupled to the analysis of protein trajectory
transitions may be broadly used in cell biology.
Methods
Cell culture. All cell lines mentioned below were cultured at 37 °C and 5% CO2 in a
humidified Forma Steri-cycle i160 CO2 incubator (Thermo Fischer Scientific) and were
grown in the described media unless otherwise specified. HFF (ATCC® CRL-2429™,
male), passage 3–6, were grown in IMDM medium (Biowest) supplemented with 10%
Gibco™ Fetal Bovine Serum, Qualified, US Origin, Standard (Sterile-Filtered) (Gibco).
RKO cells (ATCC® CRL-2577™, female), passage 3–5, were grown in DMEM sup-
plemented with 2mM glutamine (Lonza) and 10% FBS. HT29 (ATCC® HTB-38™,
female), passage 3–5 were grown in RPMI (Lonza) supplemented with 10% FBS. ESCs,
wild-type H9 (WiCell WA-09, female)61, passage 35–40 and HS980, passage 9–25 were
grown on LN-521-coated dishes in NutriStem medium (Biological Industries).
Reprograming and culturing of pluripotent cells. Human foreskin fibroblasts
(hFFs, ATCC® CRL-2429™) were reprogramed in hi11, hi12, and hi13 iPSC lines
using CoMiP 4in1 plasmid without shRNA p53 using a method described here62.
One day prior the procedure, 400 K fibroblasts were plated on a 60 mm plate. Next
day, the cells were collected using TrypLE (ThermoFisher Scientific) treatment and
electroporated using 9 µg of the CoMIP plasmid. The electroporation was per-
formed using 4D-Nucleofector (Lonza Bioscience) in P2 solution using DT-150
program. After electroporation, the cells were plated in four wells of a six-well plate
precoated with laminin-521 (BioLamina). From day 3 till day 5, the fibroblast
medium was gradually changed to TeSR™-E7™ (STEMCELL Technologies, Canada)
and from day 9 till day 14 to NutiStem (Biological Industries). From day 1 till day
9, the media were also supplemented with 0.2 mM sodium butyrate and 50 µg/mL
ascorbic acid. Between day 14 and day 21, the iPSC-looking colonies were
mechanically collected and plated into wells of a 96-well plate precoated with
laminin-521. The cells were confirmed to express pluripotency markers NANOG
(R@D Systems, Cat. No. AF1997, Lot No. KKJ0409101. Dilution 1:10), Sox-2 (R@D
Systems, Cat. No. MAB2018, Lot No. KGQ020841. Dilution 1:10), SSEA-4 (Invi-
trogen, Cat. No. MA1-021-D488, Lot No. TH274753. Dilution 1:200) by immu-
nostaining (Supplementary Fig. 2a, b). Lack of the plasmid integration was
confirmed using RT-PCR as described here62 (Supplementary Fig. 2c). Karyotyping
revealed no genetic aberrations in hi11, hi12, and hi13 cells (Supplementary
Fig. 2d–f). Pluripotency of hi11, hi12, and hi13 cells was demonstrated in in vivo
(teratoma formation in mice) and in vitro (immunostaining of embryoid bodies)
experiments (Supplementary Fig. 3a–j). The pluripotent cells were cultured on LN-
521 in NutriStem medium (Biological Industries) at 37 °C, 5% CO2 as described
here51. iPSCs were used at passage between 15 and 25 in the various experiments.
Immunostaining. Cells were cultured in 96-well plates (Corning) and fixed using
4% paraformaldehyde, permeabilized by 0.1% Triton X in PBS and blocked by 10%
bovine fetal serum (GIBCO Invitrogen Corporation) in PBS containing 0.1%
Tween-20 (Sigma–Aldrich) for 1 h at room temperature. The specimens were
incubated with primary antibody for 1.5 h at room temperature, washed three
times with 0.1% Tween-20 in PBS buffer, incubated with secondary antibody plus
40,6-diamidino-2-phenylindole (DAPI, Molecular Probes) for 1.5 h at room tem-
perature, washed three times with 0.1% Tween-20 in PBS buffer and, finally,
washed two times with PBS. The specimens were preserved in a fluorescence
mounting medium (Dako, Glostrup, Denmark) at 4 °C and analyzed using Oper-
etta fluorescence microscope (Perkin Elmer).
FACS analysis. Cells were removed from cell culture dishes using TrypLE Express,
pelleted, fixed with 4% paraformaldehyde, washed with PBS and resuspended into
single-cell suspension in FACS buffer (2% fetal bovine serum in Hank’s buffer).
Incubation with SSEA-4 antibodies was performed for 30 min at room temperature
in FACS buffer. Then, cells were washed five times with FACS buffer and placed on
ice. Cells were analyzed by FACSCalibur Flow Cytometer (Becton Dickinson, San
Jose, CA) using CellQuest software (Becton Dickinson).
Karyotyping. Karyotyping of hi11, hi12, and hi13 cells after 16, 23, and 9 passages
in culture, respectively, was done using standard Q-banding technique. The cells
were treated with 0.1 μg/mL of KaryoMAX (GIBCO Invitrogen) for 5 h. After that,
the cells were dissociated with TrypLE Express (GIBCO Invitrogen), pelleted by
centrifugation, resuspended and incubated in hypotonic solution (0.0375M KCl)
for 10 min. After the incubation, the cells were pelleted and fixed in 3:1 methanol/
acetic acid. Metaphase spreads were prepared on glass slides, G-banded by brief
exposure to trypsin and stained with 4:1 Gurr’s/Leishmann’s stain
(Sigma–Aldrich). A minimum of 10 metaphase spreads were analyzed, and an
additional 20 were counted.
Teratoma formation. Teratoma formation experiments were done by implanta-
tion of cells beneath the testicular capsule of young (8 week old) NOD SCID mice.
Three animals were used for each cell line. One million cells were injected in a 30%
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Matrigel solution in a total volume of 100 µL. Teratoma growth was observed by
weekly palpation, and the mice were sacrificed 8–12 weeks after the implantation.
The teratomas were fixed, and sections were stained with hematoxylin and eosin.
The tissue was microscopically assessed by a pathologist. All animal experiments
were performed at the infection-free animal facility of the Karolinska University
Hospital Huddinge and approved by the Ethics Committee on Animal Experiment,
Sweden (ethical approvals number S198-11 and S31-14). We have complied with
all relevant ethical regulations for animal testing and research.
Embryoid body formation. Pluripotent cells were dissociated from dishes using
treatment with TrypLE Express, pelleted by centrifugation, resuspended in
NutriStem (Saveen Werner) with 10 µM of Y-27632 (a ROCK inhibitor) and
cultured in suspension on low adhesion plates at 37 °C, 5% CO2 to form EBs. The
EBs aimed for immunostaining after 1 week in suspension were plated in gelatin-
coated tissue cell culture 96-well plates (Corning) in DMEM medium (GIBCO)
supplemented with 20% (vol/vol) fetal bovine serum (GIBCO), 2 mM l-glutamine
and 1% (wt/vol) nonessential amino acids (GIBCO) and ascorbic acid 50 µg/ml
(Sigma–Aldrich). After additional week in culture, the spread EBs were fixed,
stained for markers of all three germ layers with antibodies against smooth-muscle
actin (SMA) (Merck-Millipore, Cat. No. A5228. Dilution 1:250), MAP-2 (Milli-
pore, Cat. No. MAB3418, Lot No. LV 1796719. Dilution 1:200), and α-fetoprotein
(AFP) (R@D Systems, Cat. No. MAB1368, Lot No. HPH0209081. Dilution 1:100)
and analyzed as described above for immunostaining.
Generation of human neurons. Human neurons were generated from the hi12
line. hi12 cells were dissociated into single cells using TrypLE Select and transferred
onto nonadhesive plastic plates in DMEM/F12 containing N2 (1:100 Gibco Invi-
trogen, New York, USA, Cat. No. 17502001), as well as the SMAD inhibitors
431542 (Sigma–Aldrich/Merck, Cat. No. 301836-41-9) and LDN-193189
(Sigma–Aldrich, St. Louis, Missouri, USA, Cat. No. 1062368-24-4). For the first
24 h, 10 µM of ROCK inhibitor Y-27632 (Tocris, Cat. No. 1254) was added, leading
to the formation of floating cell aggregates. Half the medium was replaced daily. At
day 6, the floating aggregates were plated onto tissue cultured plates coated with
0.002% poly-L-ornithine (Sigma–Aldrich, St. Louis, Missouri, USA, Cat. No.
27378-49-0) and 20 µg/mL murine laminin (Sigma–Aldrich, St. Louis, Missouri,
USA, Cat. No. 114956-81-9), which led to the attachment of the cells. After
2–3 days, neural rosette structures started to emerge, which were considered neural
precursor cells. These were picked manually after 4 days and seeded at a con-
centration of 150,000 cells/cm2, in DMEM/F12, supplemented with 1% N2, 0.1%
B27 (Gibco Invitrogen, New York, USA, Cat. Num. 17504044), SHH (Sonic
Hedgehog, 200 ng/ml, R&D), and CT (1 µM CT99021, Sigma). After 7 days of
differentiation, SHH and CT were removed from media, and recombinant BDNF
(20 ng/mL, R&D), GDNF (20 ng/mL, R&D) and Ascorbic Acid (200 µM, Sigma)
were added to the culture media until day 12. Neuronal rosettes and neurons were
prepared for immunostaining as described above using rabbit anti-Nestin (Atlas
Antibodies, Cat. No. HPA007007. Dilution 1:500), mouse monoclonal anti-ZO-1
(Molecular Probes, Cat. No. 339194. Dilution 1:500), and mouse monoclonal anti-
βIII Tubulin (TUBB3) (Promega, Cat. No. G7121. Dilution 1:500).
Cell division rate measurement. hi12, hFF, and RKO cells were grown until
exponential growth phase and processed using Click-iT™ EdU Cell Proliferation Kit
for Imaging (Thermo Fischer Scientific) according to manufacturer’s instructions.
The results were analyzed using Operetta fluorescence microscope.
PISA of cell types. HFFs (passage 5), iPSCs (hi12, passage 21), ESCs (H9, passage
40), EBs (from hi12 passage 19), and RKO (passage 3) cells were grown as
described above until 80% confluence and for 21 days for EBs. Then cells were
washed with PBS and detached using TrypLE Express. The reaction was stopped by
adding fresh medium and the cells were pelleted at 340 × g for 2 min. Cell pellets
were rinsed two times with PBS and finally the cells were resuspended in 1 mL of
PBS supplemented with protease inhibitors (Roche) and 100 µL of the cell sus-
pension were distributed into 10 PCR tubes per replicate (n= 3 biologically
independent samples for each cell line). Cells were heated in a temperature range
from 48 to 59 °C and samples corresponding to each replicate were combined
together. For each cell line, one sample designated for protein expression mea-
surement was incubated at 37 °C (n= 3 biologically independent samples for each
cell line) and processed alongside the pooled samples. NP-40 (Sigma–Aldrich) was
added to lyse the cells with a final concentration of 0.4% and cells were further
lysed using repeated freeze/thaw cycles. Finally, all lysates were transferred to
ultracentrifuge tubes, placed into a Ti 42.2 rotor (Beckman-Coulter) and ultra-
centrifuged at 100,000 × g for 20 min using an Optima XPN-80 Ultracentrifuge
(Beckman-Coulter). Seventy microliters of the supernatant was collected and the
same volume of lysis buffer (8 M urea, 20 mM EPPS pH 8.5) was added and the
protein concentration was measured using Pierce bicinchoninic acid assay (BCA)
protein assay kit (Thermo Fischer Scientific) according to the manufacturer’s
protocol.
Thermal proteome profiling. HFFs, iPSCs (hi11, hi12, and hi13 cell lines), and
RKO cells were grown as described above until 80% confluence. Then cells were
washed with PBS and detached using TrypLE Express. The reaction was stopped by
adding fresh medium and the cells were pelleted at 340 × g for 2 min. Cell pellets
were rinsed two times with PBS and finally the cells were resuspended in 1 mL of
PBS supplemented with protease inhibitors (Roche) and 100 µL of the cell sus-
pension were distributed into 10 PCR tubes per replicate (n= 2 biologically
independent samples for each cell line).
For TPP in cell lysate, hi12 cells and hFFs were grown until 80% confluence,
then detached using TrypLE Express (the enzymatic activity was stopped by adding
fresh medium). Cells were then pelleted, rinsed two times with PBS and
resuspended in PBS supplemented with protease inhibitors. After that, the cellular
suspensions were freeze-thawed five times in liquid nitrogen for cell lysis with
strong vortexing in between each cycle. The insoluble fractions were pelleted for
5 min at 20,000 × g and then 100 µL of the supernatants were distributed into 10
tubes per replicate and per cell line (n= 2 biologically independent samples).
For all TPP experiments, the heating step was performed in a SimpliAmpTM
Thermal Cycler (Thermo Fischer Scientific) for 3 min at the following
temperatures: 37, 41, 44, 47, 50, 53, 56, 59, 63, and 67 °C. Then the samples were
left 3 min at RT. Samples for the lysate experiment were transferred to thick-wall
polycarbonate ultracentrifuge tubes (Beckman-Coulter) at this point and samples
for cell experiment were snap frozen in liquid nitrogen for cell lysis. The lysis was
performed using five freezing/thawing steps with vortexing after each thawing.
Finally, all lysates were transferred to ultracentrifuge tubes, placed into a Ti 42.2
rotor (Beckman-Coulter) and ultracentrifuged at 100,000 × g for 20 min using an
Optima XPN-80 Ultracentrifuge (Beckman-Coulter). Seventy microliters of the
supernatant was collected and the same volume of lysis buffer (8 M urea, 50 mM
Tris pH 8.5) was added and the protein concentration was measured using Pierce
bicinchoninic acid assay (BCA) protein assay kit (Thermo Fischer Scientific)
according to the manufacturer’s protocol.
Microarray RNA analysis. The RNA isolation had been performed using the
miRNeasy mini kit (Qiagen) according to the manufacturer’s protocol with DNaseI
(Qiagen) treatment. The RNA integrity number (RIN) values were higher than 9.5
for all RNA samples. The microarray analysis was performed according to the
manufacturer’s instructions (Termo Fischer Scientific UserGuide P/N 703174).
Procedures for cDNA synthesis, target DNA fragmentation, and labelling were
carried out according to the GeneChip WT PLUS Reagent Kit (Applied Biosys-
tems) using 500 ng of total RNA as the starting material. Hybridization on Affy-
metrix Gene Chip Human Transcriptome Array 2.0 microarrays, array washing,
staining, and scanning were performed according to the manufacturer protocol.
GeneChip Scanner 3000 7 G system (Affymetrix) was used to scan the microarrays
and the scans were converted into CEL files using the scanner software and were
then processed using the Transcriptome Analysis Console 3.0.
Expression proteomics experiments. EBs were induced as described above using
both iPSCs and ESCs and differentiated for 9 days. iPSCs, hFF, RKO, HT29, and
the human neurons differentiated from iPSCs were grown as described in the cell
culture section. Then cells were rinsed two time with PBS and lysed in the plate
with 1% SDS, 8M urea, 50 mM Tris buffer pH 8.5. The cells were then sonicated
using Branson probe sonicator for 45 s with a 3 s pulse at 30% amplitude. The
protein concentration was measured by BCA assay followed by sample preparation
for proteomics analysis.
Density gradient analysis. Sucrose density gradients were prepared prior to
sample preparation on the day of the experiment and stored at 4 °C. Two sucrose
solutions were prepared, corresponding to 10 and 50% sucrose concentration
dissolved in 20 mM HEPES pH 7.6, 100 mM KCl, 5 mM MgCl2, 10 µg/mL cyclo-
heximide, and 10 U/mL RNase inhibitor and protease inhibitor cocktail (Thermo
Fischer Scientific). Ten to fifty percent sucrose gradients were prepared using a
Gradient Master 108 (Biocomp) according to manufacturer’s instructions in
13.2 mL polypropylene ultracentrifuge tubes (Beckman-Coulter).
iPSCs and RKO cells were grown until 80% confluence in their respective
media. Then the cells were incubated with 100 ug/mL cycloheximide in their
respective medium for 10 min at 37 °C. The medium was discarded, and the cells
were transferred on ice and washed two times with ice-cold PBS containing 100 µg/
mL cycloheximide. Cells were then scraped in PBS with cycloheximide and pelleted
at 340 × g at 4 °C in a 5804 R centrifuge (Eppendorf) for 3 min. PBS was discarded
and the pellets were resuspended in lysis buffer composed of 20 mM Tris-Cl pH
7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1% Triton-X100, 100 µg/mL
cycloheximide, 25 U/mL of RNase inhibitors (Thermo Fischer Scientific) and
protease inhibitors. Cells were then vortexed for 15 s and centrifuged at 20,000 × g
for 6 min. The supernatant was transferred to a new tube and RNA levels were
measured with a DS-11 Spectrophotometer (DeNovix). Then 500 µL of the cell
lysate corresponding to 6 OD was added on top of the sucrose density gradient
after removing 500 µL from the top of the gradient.
The gradients were centrifuged in a SW 41 swinging bucket rotor (Beckman-
Coulter) in an Optima XPN-80 Ultracentrifuge at 36,000 rpm for 2 h at 4 °C with
maximum acceleration and no brake option. After centrifugation, the gradients
were placed at 4 °C and analyzed one by one using BR-188 Density Gradient
Fractionation System (Brandel). The parameters were 1.5 mL/min speed and 1.0
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abs of resolution. The chase solution consisted of 60% sucrose. Fractions were
collected every 30 s until the end of the gradient and absorbance at 245 nm was
monitored using Brandel Peak Chart recording software version 2.08.
For iPSC and RKO, fractions corresponding to the soluble part of the gradient,
40S+ 60S, 80S mRNA with 2 and 3 bound ribosomes (light polysome) and mRNA
with 4 and more bound ribosomes (heavy polysome) were selected (Fig. 4a).
Proteins were precipitated using methanol chloroform followed by sample
preparation for proteomics analysis.
SBDS siRNA treatment of hFF. hFF were seeded in IMDM medium supple-
mented with 10% FBS at a density of 30,000 per well in six-well plates. 24 h later,
they were transfected with either SBDS or scrambled siRNA (Qiagen) using lipo-
fectamine 2000 (Thermo Fischer Scientific) according to the manufacturer’s
instructions. All siRNA and primers used in this study are presented in Supple-
mentary Table 1. Briefly, for each reaction 5 µL of lipofectamine were added to
240 µL of IMDM medium without serum and incubated at RT for 5 min. Then,
5 µL of 20 µM solution of either SBDS or AllStars negative control siRNA (Qiagen)
(Scrambled siRNA 1) were added, and the mix was incubated at RT for 20 min.
SBDS siRNA correspond to Hs_SBDS_5 FlexiTube siRNA (SBDS siRNA 1) from
Qiagen, which is a functionally verified siRNA targeting 5′-TTGGAAGTACTCA
ATCTGAAA-3′ sequence with 5′-GGAAGUACUCAAUCUGAAATT-3′ (sense)
and 5′-UUUCAGAUUGAGUACUUCCAA-3′ (antisense) siRNA duplex sequen-
ces. hFF medium was replaced by 1 mL of fresh medium and the respective lipo-
fectamine/siRNA reactions were added drop by drop on top of the hFF. Cells were
incubated overnight with the lipofectamine/siRNA mix and then the medium was
changed for fresh medium. After 2- and 4-days triplicates of SBDS siRNA and
AllStars negative control siRNA treated hFF were washed two times with PBS and
lysed using 1% SDS, 8 M urea, 50 mM Tris pH 8.5. Finally, the cells were scraped
and sonicated as described in the Expression proteomics section, followed by
sample preparation for proteomics analysis.
SBDS KD in EBs. EBs were differentiated from hi12 as described in Fig. 7a. Three
days after plating of EBs on gelatin (6th day of the differentiation), they were
treated with either SBDS or AllStars (scrambled) siRNA following the same pro-
cedure as for hFFs except that the medium used was MEM. Three days later (9th
day of the EBs differentiation), cells were rinsed two times with PBS to prepare for
protein and RNA extraction. For proteomics analysis, cells were lysed using 1%
SDS, 8 M urea, 50 mM Tris pH 8.5. Later, cells were harvested and sonicated as
described in the Expression proteomics section, followed by sample preparation for
proteomics analysis. For qRT-PCR, samples were prepared as described below.
SBDS KD in PSCs transferred on Geltrex. hi12 and H9 were maintained as
described above, when reaching full confluence cells were detached and transferred
to dish coated with Geltrex™ LDEV-Free, hESC-Qualified, Reduced Growth Factor
Basement Membrane Matrix (Gibco™) at 1/20 dilution in Nutristem medium. Two
days after plating, cells were treated with the two siRNAs (Scrambled siRNA 1 and
SBDS siRNA 1) as described above. One new siRNA targeting SBDSmRNA, and one
new control were also used. The control was Silencer™ Select Negative Control No.
1 siRNA (Scrambled siRNA 2) (cat#4390843, Ambion™) and the siRNA targeting
SBDS was Silencer® Select siRNA number s27482 (Ambion™)(SBDS siRNA 2),
which is a functionally verified siRNA targeting 5′-CGAAAUCGCCUGCUACAA
A-3′ sequence with 5′-CGAAAUCGCCUGCUACAAATT -3′ (sense) and 5′-UUU
GUAGCAGGCGAUUUCGAA-3′ (antisense) siRNA duplex sequences. Cells were
passaged when reaching confluence and another round of treatment was performed
for 3 days. After this, cells were rinsed two times with PBS to prepare for protein and
RNA extraction and qRT-PCR analysis as described below.
SBDS protein knockin in hi12 and H9. hi12 and H9 were grown as described
above until around 80% confluence, then they were treated with lipofectamine
containing the plasmid with SBDS gene or empty as a control. For each reaction
2 µg of plasmid were added to 4 µl of lipofectamine 2000 in 200 µl DMEM medium,
which was then added on top of the cells. The plasmid characteristic was as follow:
Vector: pcDNA3.1/Zeo (−), Ampicillin, 5014 bp (GeneScript). The SBDS gene
sequence was inserted in 5′ Default Cloning Site: XhoI CTCGAG. 5′ start codon:
ATG, 3′ stop codon: TGA, 3′ default cloning site: BamHI GGATCC. The clone ID
is OHu18189C, containing the following sequence: ORF Clones (Accession No.):
















AGAAGGAGATGAGAAATTTGAATGAGGATCC. The day after transfection,
the medium was replaced with fresh Nutristem medium containing 5 µg/ml Zeo-
cin™ Selection Reagent (Gibco™). After 1 day of treatment cells were rinsed two
times with PBS to prepare for protein and RNA extraction and qRT-PCR analysis
as described below.
Since there was no increase in expression of SBDS in hi12 after transfection
with lipofectamines, we opted for transfection using electroporation. hi12 at full
confluence were detached and 3 × 106 cells per sample were aliquoted, prepared for
electroporation using P3 Primary Cell 4D-NucleofectorTM X Kit L (Lonza)
according to manufacturer’s protocol, with 5 µg of the same pcDNA3.1/Zeo (−)
plasmid as above, containing SBDS gene or empty, and cells were electroporated in
a 4D-Nucleofector® (Lonza) using a CT150 pulse. After the pulse, cells were seeded
on laminin-521-coated plates in Nutristem medium. After 48 h of culture, cells
were treated with 5 µg/ml Zeocin for an additional 48 h and then rinsed two times
with PBS to prepare for protein and RNA extraction and qRT-PCR analysis as
described below.
Quantitative real-time PCR (qRT-PCR). Total RNA was isolated using RNAeasy
Microprep kit (QIAGEN) according to the manufacturer’s instructions. cDNA was
synthesized with 0.2 µg of total RNA in 20 µL reaction mixture using High Capacity
RNA-to-cDNA kit (Thermo Fischer Scientific) according to the manufacturer’s
instructions. Real-time quantitative RT-PCR Taqman assays were performed using
CFX Connect™ Real-Time PCR Detection System (Bio-Rad). All reactions were
done in quadruplicates with the use of a pre-developed gene expression assay mix
(Applied Biosystems) containing primers and a probe for the messenger RNA of
interest. Additionally, each experiment included the assay mix for GAPDH for
normalization of the RNA input. All data were analyzed using CFX manager
version 3.0 (Bio-Rad). All the signals appearing at the 35th and later cycles were
regarded as not detected.
Protein sample preparation for expression proteomics and TMT10 and TMT11
labeling. For all proteomics experiments, 50 µg of proteins were used in sample
preparation. Reduction was performed using 5 mM DTT at RT for 1 h followed by
alkylation using 15 mM IAA at RT in the dark for 1 h. The reaction was quenched
by adding 10 mM DTT. Then methanol/chloroform precipitation was performed
as followed: 3 sample volume of methanol were added, then 1 sample volume of
chloroform and 3 volumes of water. Samples were vortexed between each step and
then centrifugated at 20,000 × g for 10 min at 4 °C. The aqueous layer was removed,
and the protein pellet was rinsed with one sample volume of methanol, vortexed,
and centrifuged using the same speed as in the previous step. Finally, all the liquid
was removed, and the protein pellet was air-dried.
Air-dried protein pellets were resuspended in 8M urea, 20 mM EPPS pH 8.5.
The samples were diluted once with by adding 20 mM EPPS pH 8.5 (4 M urea) and
lysyl endopeptidase digestion was carried out at a 1:100 ratio (LysC/protein, w/w)
overnight at RT. The following day, samples were diluted four times (1 M urea)
with 20 mM EPPS pH 8.5, then tryptic digestion was performed for 6 h at RT using
a 1:100 ratio (Trypsin/protein, w/w). For PISA, a sample composed of one tenth of
each sample pooled together was prepared as technical replicate for normalization
purposes. After that, TMT10 and TMT11 labeling were performed during 2 h at RT
by adding 0.2 mg of reagent dissolved in dry ACN according to manufacturer’s
instructions and a final ACN concentration of 20%. The reaction was then
quenched by adding triethylamine to a final 0.5% concentration and incubated
15 min at RT. The samples were combined resulting in one pooled sample per
replicate containing each temperature. After that, the samples were acidified to
pH < 3 using TFA, desalted using Sep Pack (Waters) and vacuum dried overnight
using miVac DNA (Genevac).
High-pH reversed-phase peptide fractionation. For experiments 2–5 and 10
(Supplementary Table 2) 70 µg of peptides were resuspended into 300 µL of 0.1%
TFA and fractionated using Pierce™ High pH Reversed-Phase Peptide Fractiona-
tion Kit (Thermo Fischer Scientific) according to manufacturer’s protocol, resulting
in 8 fractions per samples. Samples were then dried overnight in a Speedvac.
For experiments 1, 7–9, 11, and 12 (Supplementary Table 2), 150 µg of peptides
were resuspended into 20 mM NH4OH. Then, samples were off-line high-pH
reversed-phase fractionated63,64 using an UltimateTM 3000 RSLCnano System
(Dionex) equipped with a XBridge Peptide BEH 25 cm column of 2.1 mm internal
diameter, packed with 3.5 µm C18 beads having 300 Å pores (Waters). The mobile
phase consisted of buffer A (20 mM NH4OH) and buffer B (100% ACN). The
gradient started from 1% B to 23.5% in 42 min, then to 54% B in 9 min, 63% B in
2 min and stayed at 63% B for 5 min and finally back to 1% B and stayed at 1% B
for 7 min. This resulted in 96 fractions that were concatenated into 24 fractions and
dried o/n using miVac DNA.
Mass spectrometry analysis. Prior to mass spectrometry analysis, all samples
were resuspended in 2% ACN and 0.1% FA at a concentration of 0.2 µg/µL and
1 µg was injected into the respective LC system (summarized in Supplementary
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Table 2). Mass spectra were acquired using the parameters listed in Supplementary
Table 3.
Oxygen consumption and extracellular acidification. Metabolic flux analysis was
performed on hi12, hFF, and RKO cells using Seahorse XF24 Extracellular Flux
Analyzer (Seahorse Biosciences, Billerica, MA). Two days before the experiment
15,000 cells/well were seeded. hi12 were seeded after coating the wells with
laminin-521. The day of the experiment the medium was changed in 500 µL
DMEM/F12 low buffer capacity containing either 2% FBS (hFF, RKO cells) or
20 µL/mL of E8 supplements (hi12 cells). The cells were incubated at 37 °C without
CO2 1 h prior to experiment.
The oxygen consumption rate (OCR) and acidification rate (ECAR) were
recorded at basal level and following injection of oligomycin (1 µM final), carbonyl-
cyanide 4-trifluoromethoxy-phenylhydrazone FCCP (1–2 µM) and mixture of
rotenone and antimycin A (1 μM). Running template was 2 min mix, 1 min wait
and 4 min measure. All chemicals were purchased from Sigma–Aldrich. Data were
normalized on the number of cells per well and against basal OCR and ECAR.
Normalization for cell number was carried out staining the nuclei with Hoescht
33342 (Molecular Probes) for 10 min and then imaging each well using BD
pathway 855 (BD Biosciences, Franklin Lakes, U.S.) with ×10 objective and
montage 5 × 4. Cell numbers were counted with Cell profiler software.
Protein synthesis rate measurement in hi12, hFF, and RKO. Protein synthesis
rate in hi12, hFF, and RKO was measured using Click-iT® Plus OPP Protein
Synthesis Assay (Thermo Fischer Scientific). Briefly hi12, hFF, and RKO were
treated with OPPuro at exponential growth phase and samples were processed
according to manufacturer’s protocol and prepared for flow cytometry analysis.
Single-cell suspension was prepared by filtering through 40 µm cell strainers (BD
Falcon). NuclearMask™ Blue stain was used to gate on cells, after which mean
fluorescence intensity (MFI) of the FITC channel was calculated. A SORP BD
LSRII Analytic Flow Cytometer (BD Biosciences) was used for acquisition and the
data was analyzed with Flowjo 8.8.6 (Tree Star Inc., OP, USA). P-values were
calculated using a two-sided Student t-test.
Protein synthesis rate measurement in SBDS siRNA treated hFF. 3000 hFF
were seeded in 96-well plates and the day after they were treated with SBDS siRNA
and AllStars negative control siRNA following the same procedure as described
above for 3 days (n= 6 biologically independent samples for SBDS and control).
Then protein synthesis rate was measured using OPPuro according to manu-
facturer’s protocol and analyzed using Operetta.
Quantification and statistical analysis
TMT10 labelling quantification. Protein identification and quantification were
performed using MaxQuant software (version 1.6.2.3). MS2 was selected as the
quantification mode with TMT10 or TMT11 as the modification. Acetylation of N-
terminal, oxidation of methionine and deamidation of asparagine and glutamine
were selected as variable modifications. Carbamidomethylation of the cysteine was
selected as fixed modification. The Andromeda search engine was using the Uni-
Prot human database 2019_05 excluding protein isoforms (73 910 entries) with the
precursor mass tolerance for the first searches and the main search set to 20 and 4.5
ppm, respectively. Trypsin was selected as the enzyme, with up to two missed
cleavages allowed; the peptide minimal length was set to seven amino acids. Default
parameters were used for the instrument setting. The FDR was set to 0.01 for
peptides and proteins. “Match between runs” option was used with a time window
of 0.7 min and an alignment time window of 20 min.
Analysis of microarray mRNA data. Statistical analysis of differential gene
expression was performed using a nonpaired one-way (ANOVA) test with the
Benjamini–Hochberg correction for multiple comparisons. For the detection of
differentially expressed genes, the threshold for the adjusted p-value was set at 0.01,
and the threshold for the fold change (FC) was set at 2.0. Probe sets with no
associated Gene Symbol were excluded from the analyzes.
Data normalization and statistical analysis. All data analysis and plots were pro-
duced using R version 3.6.1 and Excel 2016. In all proteomics analysis, individual
protein abundances (corrected reporter ion intensity of LFQ intensity) were nor-
malized by the sum of all protein abundances in the corresponding sample.
Analysis of TPP data was performed using TPP R package version 3.13 (Bio-
conductor) according to the procedure described by Franken et al.10. Estimated
protein melting points (Tm) were extracted from the result file produced by the
TPP package and used for data analysis (Supplementary Data 3). Comparison
between two sample groups were assessed using two-tailed unpaired t-test unless
otherwise specified. Data are presented as mean ± standard error of the mean,
unless otherwise stated. P-values lower than 0.05 were considered to be statistically
significant. r for the corresponding plots were calculated using Pearson correlation.
For the analysis of the data from metabolic flux analysis, a Grubb’s test was used to
remove outliers among biological replicates. GO pathways enrichment were done
using Gene Ontology enRIchment anaLysis and visuaLizAtion tool (Gorilla)65,66 or
DAVID version 6.8. For pathways enrichment significance, we considered
pathways with p-values corrected by Benjamini–Hochberg procedure lower
than 0.05. Only proteins identified with two peptides or more and without
missing values in any of the samples and replicates were considered for statistical
analysis.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
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exchange.org) via the PRIDE partner repository with dataset identifier PXD018453
(PISA-Express data), PXD014830 (TPP data of hi11, hi12, hi13, hFF, RKO in cells; TPP
data of hi12 and hFF in cell lysates; ribosomal protein expression data in hi12 and RKO;
protein expression data in hFF, hi12, HT29, Neurons, EBs, RKO; SBDS KD protein
expression data in hFF; SBDS KD protein expression data after EB induction in hi12) and
PXD015874 (Protein expression data of EB induction in H9 and HS980). The microarray
RNA analysis data were deposited to GEO repository under the accession number
GSE135409. Statistics from the TPP data generated by the TPP R package version 3.13
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zenodo.5018241. The ProteoTracker tool is freely available at http://www.proteotracker.
genexplain.com. Source data are provided with this paper.
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